A Safety, Tolerability, Pharmacokinetic Study of SHR-6934 Injection in Healthy Subjects
Status:
NOT_YET_RECRUITING
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This study was a randomized, double-blind, single-dose and multi-dose, placebo-controlled phase clinical trial. Six dose groups were planned for the SAD part of the study and four dose groups were planned for the MAD part. A total of 88 healthy subjects were included.